Expression of major histocompatibility complex (MHC) class II, but not MHC class I, predicts outcome in patients with classical Hodgkin lymphoma (cHL) treated with nivolumab (programmed death-1 [PD-1] blockade) Meeting Abstract
| Authors: | Roemer, M. G. M.; Redd, R. A.; Cader, F. Z.; Pak, C. J.; Abdelrahman, S.; Ouyang, J.; Sasse, S.; Younes, A.; Fanale, M. A.; Santoro, A.; Zinzani, P. L.; Timmerman, J. M.; Collins, G.; Ramchandren, R.; Cohen, J. B.; De Boer, J. P.; Kuruvilla, J.; Savage, K. J.; Trneny, M.; Ansell, S. M.; Sacchi, M.; Farsaci, B.; Sumbul, A.; Armand, P.; Neuberg, D. S.; Pinkus, G. S.; Ligon, A. H.; Rodig, S. J.; Shipp, M. A. |
| Abstract Title: | Expression of major histocompatibility complex (MHC) class II, but not MHC class I, predicts outcome in patients with classical Hodgkin lymphoma (cHL) treated with nivolumab (programmed death-1 [PD-1] blockade) |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419403274 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.1450.1450 |
| Notes: | Meeting Abstract: 1450 -- Source: Wos |
